Does the media prefer ALT or SPRB?

In the previous week, Altimmune had 2 more articles in the media than Spruce Biosciences. MarketBeat recorded 6 mentions for Altimmune and 4 mentions for Spruce Biosciences. Altimmune's average media sentiment score of 0.73 beat Spruce Biosciences' score of 0.66 indicating that Altimmune is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Altimmune 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Spruce Biosciences 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer DNA or SPRB?

In the previous week, Ginkgo Bioworks and Ginkgo Bioworks both had 4 articles in the media. Spruce Biosciences' average media sentiment score of 0.66 beat Ginkgo Bioworks' score of 0.16 indicating that Spruce Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ginkgo Bioworks 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Spruce Biosciences 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is TECX or SPRB more profitable?

Tectonic Therapeutic's return on equity of -32.33% beat Spruce Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Tectonic Therapeutic N/A -32.33% -30.92% Spruce Biosciences N/A -155.40% -101.67%

Does the media prefer TECX or SPRB?

In the previous week, Spruce Biosciences had 1 more articles in the media than Tectonic Therapeutic. MarketBeat recorded 4 mentions for Spruce Biosciences and 3 mentions for Tectonic Therapeutic. Spruce Biosciences' average media sentiment score of 0.66 beat Tectonic Therapeutic's score of 0.62 indicating that Spruce Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tectonic Therapeutic 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Spruce Biosciences 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer PRME or SPRB?

In the previous week, Spruce Biosciences had 2 more articles in the media than Prime Medicine. MarketBeat recorded 4 mentions for Spruce Biosciences and 2 mentions for Prime Medicine. Prime Medicine's average media sentiment score of 0.94 beat Spruce Biosciences' score of 0.66 indicating that Prime Medicine is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Prime Medicine 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Spruce Biosciences 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation and earnings, SPRB or EIKN?

EIKN has lower revenue, but higher earnings than Spruce Biosciences. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Spruce Biosciences $4.91M 28.72 -$38.97M -$36.60 N/A EIKN N/A N/A N/A N/A N/A

Is SPRB or EIKN more profitable?

EIKN's return on equity of 0.00% beat Spruce Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Spruce Biosciences N/A -155.40% -101.67% EIKN N/A N/A N/A

Spruce Biosciences (SPRB) Competitors

$51.27 +2.08 (+4.23%)

Closing price 04:00 PM Eastern

Extended Trading

$51.44 +0.17 (+0.33%)

As of 05:39 PM Eastern

Compare

SPRB vs. ALT, DNA, TECX, PRME, and EIKN

Should you buy Spruce Biosciences stock or one of its competitors? MarketBeat compares Spruce Biosciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Spruce Biosciences include Altimmune (ALT), Ginkgo Bioworks (DNA), Tectonic Therapeutic (TECX), Prime Medicine (PRME), and EIKN (EIKN). These companies are all part of the "pharmaceutical products" industry.

How does Spruce Biosciences compare to Altimmune?

Altimmune (NASDAQ:ALT) and Spruce Biosciences (NASDAQ:SPRB) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, profitability, earnings, risk, media sentiment, institutional ownership and valuation.

Altimmune currently has a consensus target price of $16.67, indicating a potential upside of 446.45%. Spruce Biosciences has a consensus target price of $186.60, indicating a potential upside of 263.96%. Given Altimmune's higher possible upside, equities research analysts plainly believe Altimmune is more favorable than Spruce Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Altimmune	2 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.50
Spruce Biosciences	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50

78.1% of Altimmune shares are held by institutional investors. Comparatively, 91.7% of Spruce Biosciences shares are held by institutional investors. 1.6% of Altimmune shares are held by company insiders. Comparatively, 4.3% of Spruce Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Altimmune has a beta of 0.18, suggesting that its stock price is 82% less volatile than the broader market. Comparatively, Spruce Biosciences has a beta of 3.26, suggesting that its stock price is 226% more volatile than the broader market.

Spruce Biosciences has higher revenue and earnings than Altimmune. Altimmune is trading at a lower price-to-earnings ratio than Spruce Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Altimmune	$40K	14,828.34	-$88.09M	-$0.93	N/A
Spruce Biosciences	$4.91M	28.72	-$38.97M	-$36.60	N/A

In the previous week, Altimmune had 2 more articles in the media than Spruce Biosciences. MarketBeat recorded 6 mentions for Altimmune and 4 mentions for Spruce Biosciences. Altimmune's average media sentiment score of 0.73 beat Spruce Biosciences' score of 0.66 indicating that Altimmune is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Altimmune	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Spruce Biosciences	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Spruce Biosciences has a net margin of 0.00% compared to Altimmune's net margin of -214,860.98%. Altimmune's return on equity of -42.57% beat Spruce Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Altimmune	-214,860.98%	-42.57%	-35.57%
Spruce Biosciences	N/A	-155.40%	-101.67%

Summary

Altimmune beats Spruce Biosciences on 8 of the 15 factors compared between the two stocks.

How does Spruce Biosciences compare to Ginkgo Bioworks?

Ginkgo Bioworks (NYSE:DNA) and Spruce Biosciences (NASDAQ:SPRB) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their media sentiment, analyst recommendations, profitability, earnings, risk, institutional ownership, dividends and valuation.

78.6% of Ginkgo Bioworks shares are held by institutional investors. Comparatively, 91.7% of Spruce Biosciences shares are held by institutional investors. 12.7% of Ginkgo Bioworks shares are held by insiders. Comparatively, 4.3% of Spruce Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Spruce Biosciences has lower revenue, but higher earnings than Ginkgo Bioworks. Ginkgo Bioworks is trading at a lower price-to-earnings ratio than Spruce Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ginkgo Bioworks	$170.15M	3.60	-$312.76M	-$5.36	N/A
Spruce Biosciences	$4.91M	28.72	-$38.97M	-$36.60	N/A

Ginkgo Bioworks currently has a consensus price target of $8.50, indicating a potential downside of 9.33%. Spruce Biosciences has a consensus price target of $186.60, indicating a potential upside of 263.96%. Given Spruce Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Spruce Biosciences is more favorable than Ginkgo Bioworks.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ginkgo Bioworks	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67
Spruce Biosciences	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, Ginkgo Bioworks and Ginkgo Bioworks both had 4 articles in the media. Spruce Biosciences' average media sentiment score of 0.66 beat Ginkgo Bioworks' score of 0.16 indicating that Spruce Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ginkgo Bioworks	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Spruce Biosciences	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Spruce Biosciences has a net margin of 0.00% compared to Ginkgo Bioworks' net margin of -215.41%. Ginkgo Bioworks' return on equity of -56.08% beat Spruce Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ginkgo Bioworks	-215.41%	-56.08%	-26.06%
Spruce Biosciences	N/A	-155.40%	-101.67%

Ginkgo Bioworks has a beta of 1.77, suggesting that its share price is 77% more volatile than the broader market. Comparatively, Spruce Biosciences has a beta of 3.26, suggesting that its share price is 226% more volatile than the broader market.

Summary

Spruce Biosciences beats Ginkgo Bioworks on 10 of the 15 factors compared between the two stocks.

How does Spruce Biosciences compare to Tectonic Therapeutic?

Tectonic Therapeutic (NASDAQ:TECX) and Spruce Biosciences (NASDAQ:SPRB) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, dividends, valuation, risk, earnings, media sentiment and institutional ownership.

In the previous week, Spruce Biosciences had 1 more articles in the media than Tectonic Therapeutic. MarketBeat recorded 4 mentions for Spruce Biosciences and 3 mentions for Tectonic Therapeutic. Spruce Biosciences' average media sentiment score of 0.66 beat Tectonic Therapeutic's score of 0.62 indicating that Spruce Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tectonic Therapeutic	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Spruce Biosciences	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Tectonic Therapeutic's return on equity of -32.33% beat Spruce Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tectonic Therapeutic	N/A	-32.33%	-30.92%
Spruce Biosciences	N/A	-155.40%	-101.67%

Spruce Biosciences has higher revenue and earnings than Tectonic Therapeutic. Tectonic Therapeutic is trading at a lower price-to-earnings ratio than Spruce Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tectonic Therapeutic	N/A	N/A	-$74.15M	-$4.46	N/A
Spruce Biosciences	$4.91M	28.72	-$38.97M	-$36.60	N/A

Tectonic Therapeutic presently has a consensus target price of $80.67, indicating a potential upside of 158.80%. Spruce Biosciences has a consensus target price of $186.60, indicating a potential upside of 263.96%. Given Spruce Biosciences' higher probable upside, analysts plainly believe Spruce Biosciences is more favorable than Tectonic Therapeutic.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tectonic Therapeutic	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	3.00
Spruce Biosciences	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50

62.6% of Tectonic Therapeutic shares are held by institutional investors. Comparatively, 91.7% of Spruce Biosciences shares are held by institutional investors. 39.8% of Tectonic Therapeutic shares are held by company insiders. Comparatively, 4.3% of Spruce Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Tectonic Therapeutic has a beta of 3.27, suggesting that its share price is 227% more volatile than the broader market. Comparatively, Spruce Biosciences has a beta of 3.26, suggesting that its share price is 226% more volatile than the broader market.

Summary

Spruce Biosciences beats Tectonic Therapeutic on 8 of the 15 factors compared between the two stocks.

How does Spruce Biosciences compare to Prime Medicine?

Prime Medicine (NASDAQ:PRME) and Spruce Biosciences (NASDAQ:SPRB) are both small-cap pharmaceutical products companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, analyst recommendations, media sentiment, risk, earnings, valuation, institutional ownership and dividends.

Spruce Biosciences has higher revenue and earnings than Prime Medicine. Prime Medicine is trading at a lower price-to-earnings ratio than Spruce Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prime Medicine	$4.63M	138.49	-$201.14M	-$1.23	N/A
Spruce Biosciences	$4.91M	28.72	-$38.97M	-$36.60	N/A

70.4% of Prime Medicine shares are held by institutional investors. Comparatively, 91.7% of Spruce Biosciences shares are held by institutional investors. 22.7% of Prime Medicine shares are held by insiders. Comparatively, 4.3% of Spruce Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Spruce Biosciences had 2 more articles in the media than Prime Medicine. MarketBeat recorded 4 mentions for Spruce Biosciences and 2 mentions for Prime Medicine. Prime Medicine's average media sentiment score of 0.94 beat Spruce Biosciences' score of 0.66 indicating that Prime Medicine is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Prime Medicine	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Spruce Biosciences	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Prime Medicine currently has a consensus price target of $7.65, indicating a potential upside of 115.49%. Spruce Biosciences has a consensus price target of $186.60, indicating a potential upside of 263.96%. Given Spruce Biosciences' higher possible upside, analysts plainly believe Spruce Biosciences is more favorable than Prime Medicine.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prime Medicine	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67
Spruce Biosciences	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50

Prime Medicine has a beta of 2.35, suggesting that its stock price is 135% more volatile than the broader market. Comparatively, Spruce Biosciences has a beta of 3.26, suggesting that its stock price is 226% more volatile than the broader market.

Spruce Biosciences has a net margin of 0.00% compared to Prime Medicine's net margin of -4,917.55%. Spruce Biosciences' return on equity of -155.40% beat Prime Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Prime Medicine	-4,917.55%	-188.82%	-60.97%
Spruce Biosciences	N/A	-155.40%	-101.67%

Summary

Spruce Biosciences beats Prime Medicine on 10 of the 17 factors compared between the two stocks.

How does Spruce Biosciences compare to EIKN?

Spruce Biosciences (NASDAQ:SPRB) and EIKN (NASDAQ:EIKN) are both small-cap pharmaceutical products companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, media sentiment, profitability, analyst recommendations, institutional ownership, earnings, dividends and risk.

In the previous week, Spruce Biosciences had 3 more articles in the media than EIKN. MarketBeat recorded 4 mentions for Spruce Biosciences and 1 mentions for EIKN. EIKN's average media sentiment score of 0.96 beat Spruce Biosciences' score of 0.66 indicating that EIKN is being referred to more favorably in the news media.

Company	Overall Sentiment
Spruce Biosciences	Positive
EIKN	Positive

EIKN's return on equity of 0.00% beat Spruce Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Spruce Biosciences	N/A	-155.40%	-101.67%
EIKN	N/A	N/A	N/A

EIKN has lower revenue, but higher earnings than Spruce Biosciences.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spruce Biosciences	$4.91M	28.72	-$38.97M	-$36.60	N/A
EIKN	N/A	N/A	N/A	N/A	N/A

Spruce Biosciences currently has a consensus target price of $186.60, suggesting a potential upside of 263.96%. EIKN has a consensus target price of $25.20, suggesting a potential upside of 132.47%. Given Spruce Biosciences' higher probable upside, research analysts plainly believe Spruce Biosciences is more favorable than EIKN.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spruce Biosciences	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50
EIKN	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

91.7% of Spruce Biosciences shares are held by institutional investors. 4.3% of Spruce Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Spruce Biosciences beats EIKN on 5 of the 9 factors compared between the two stocks.

Get Spruce Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SPRB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SPRB vs. The Competition

Export

Metric	Spruce Biosciences	Pharmaceutical Industry	Medical Sector	NASDAQ Exchange
Market Cap	$140.99M	$934.65M	$6.41B	$12.58B
Dividend Yield	N/A	4.84%	2.75%	5.26%
P/E Ratio	-1.40	1.46	21.25	26.28
Price / Sales	28.72	120.60	561.59	114.77
Price / Cash	N/A	20.06	43.49	56.90
Price / Book	4.07	7.69	10.60	7.33
Net Income	-$38.97M	-$3.80M	$3.56B	$337.06M
7 Day Performance	0.37%	2.50%	2.84%	3.43%
1 Month Performance	-7.65%	75.56%	6.16%	7.24%
1 Year Performance	883.60%	120.46%	36.73%	37.98%

Spruce Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SPRB Spruce Biosciences	2.4778 of 5 stars	$51.27 +4.2%	$186.60 +264.0%	+924.8%	$140.99M	$4.91M	N/A	20	News Coverage Analyst Forecast
ALT Altimmune	3.0413 of 5 stars	$2.93 +1.0%	$16.67 +468.8%	-44.1%	$569.80M	$40K	N/A	50
DNA Ginkgo Bioworks	1.2041 of 5 stars	$8.71 +3.6%	$8.50 -2.4%	+27.7%	$568.94M	$170.15M	N/A	640
TECX Tectonic Therapeutic	2.4019 of 5 stars	$29.99 +3.0%	$80.67 +169.0%	+38.2%	$565.91M	N/A	N/A	120	Analyst Upgrade Gap Up
PRME Prime Medicine	2.1614 of 5 stars	$2.97 flat	$7.65 +157.6%	N/A	$536.44M	$4.63M	N/A	N/A	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SPRB) was last updated on 5/29/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Spruce Biosciences (SPRB) Competitors

SPRB vs. ALT, DNA, TECX, PRME, and EIKN

How does Spruce Biosciences compare to Altimmune?

Summary

How does Spruce Biosciences compare to Ginkgo Bioworks?

Summary

How does Spruce Biosciences compare to Tectonic Therapeutic?

Summary

How does Spruce Biosciences compare to Prime Medicine?

Summary

How does Spruce Biosciences compare to EIKN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SPRB vs. The Competition

Spruce Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Spruce Biosciences (SPRB) Competitors

SPRB vs. ALT, DNA, TECX, PRME, and EIKN

How does Spruce Biosciences compare to Altimmune?

Do analysts rate ALT or SPRB?

Do institutionals & insiders believe in ALT or SPRB?

Which has more risk & volatility, ALT or SPRB?

Which has stronger earnings and valuation, ALT or SPRB?

Does the media prefer ALT or SPRB?

Is ALT or SPRB more profitable?

Summary

How does Spruce Biosciences compare to Ginkgo Bioworks?

Do insiders & institutionals believe in DNA or SPRB?

Which has better valuation and earnings, DNA or SPRB?

Do analysts rate DNA or SPRB?

Does the media prefer DNA or SPRB?

Is DNA or SPRB more profitable?

Which has more risk and volatility, DNA or SPRB?

Summary

How does Spruce Biosciences compare to Tectonic Therapeutic?

Does the media prefer TECX or SPRB?

Is TECX or SPRB more profitable?

Which has preferable earnings & valuation, TECX or SPRB?

Do analysts rate TECX or SPRB?

Do insiders and institutionals believe in TECX or SPRB?

Which has more volatility and risk, TECX or SPRB?

Summary

How does Spruce Biosciences compare to Prime Medicine?

Which has stronger valuation & earnings, PRME or SPRB?

Do institutionals & insiders believe in PRME or SPRB?

Does the media prefer PRME or SPRB?

Do analysts rate PRME or SPRB?

Which has more risk & volatility, PRME or SPRB?

Is PRME or SPRB more profitable?

Summary

How does Spruce Biosciences compare to EIKN?

Does the media favor SPRB or EIKN?

Is SPRB or EIKN more profitable?

Which has preferable valuation and earnings, SPRB or EIKN?

Do analysts rate SPRB or EIKN?

Do insiders & institutionals have more ownership in SPRB or EIKN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SPRB vs. The Competition

Spruce Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools